195 results on '"Happich, Michael"'
Search Results
2. Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer’s Disease
3. The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective
4. Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review
5. Health State Valuation Methods and Reference Points: The Case of Tinnitus
6. Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain
7. Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective
8. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002—Results from the diabetic microvascular complications (DIMICO) study
9. Diabetic retinopathy and health-related quality of life
10. The economic burden of diabetic retinopathy in Germany in 2002
11. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease
12. Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set
13. Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
14. An exponential representation of health state utility
15. Valuing the health state ‘tinnitus’: Differences between patients and the general public
16. Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study
17. Practical implications of using real-world evidence (RWE) in comparative effectiveness research: Learnings from IMI-GetReal
18. Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life – A Case Study of the Innovative Medicines Initiative.
19. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer’s disease dementia
20. What Drives Country Differences in Cost of Alzheimer's Disease? : An Explanation from Resource Use in the GERAS Study
21. Additional file 1: of How to deal with missing longitudinal data in cost of illness analysis in Alzheimerâ s diseaseâ suggestions from the GERAS observational study
22. Additional file 2: of How to deal with missing longitudinal data in cost of illness analysis in Alzheimerâ s diseaseâ suggestions from the GERAS observational study
23. Clinical and cost implications of beta-amyloid detection with Aβ-PET imaging in early Alzheimer’s disease – the case of florbetapir
24. An exponential representation of health state utility
25. Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetReal
26. What Drives Country Differences in Cost of Alzheimer’s Disease? An Explanation from Resource Use in the GERAS Study
27. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer’s disease – the case of florbetapir
28. How to deal with missing longitudinal data in cost of illness analysis in Alzheimer’s disease—suggestions from the GERAS observational study
29. Excess Costs Associated with Possible Misdiagnosis of Alzheimer’s Disease Among Patients with Vascular Dementia in a UK CPRD Population
30. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results
31. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
32. Risk-Adjusted Capitation Payments: How Well Do Principal Inpatient Diagnosis-Based Models Work in the German Situation? Results From a Large Data Set
33. Impact of Pretreatment With Antidepressants on the Efficacy of Duloxetine in Terms of Mood Symptoms and Functioning
34. Effectiveness of Duloxetine Compared With Pregabalin and Gabapentin in Diabetic Peripheral Neuropathic Pain
35. Systematic Literature Review and Meta-Analysis of Diagnostic Test Accuracy in Alzheimer's Disease and Other Dementia Using Autopsy as Standard of Truth
36. P4‐339: EXCESS COSTS ASSOCIATED WITH POSSIBLE MISDIAGNOSIS OF ALZHEIMER'S DISEASE AMONG PATIENTS WITH VASCULAR DEMENTIA IN A UK CPRD POPULATION
37. Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer’s disease: a retrospective, matched case–control study in the United Kingdom
38. Cost Effectiveness of Duloxetine for Osteoarthritis: A Quebec Societal Perspective
39. The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis
40. Health care costs before and after diagnosis of depression in patients with unexplained pain: a retrospective cohort study using the United Kingdom General Practice Research Database
41. Incidence of diabetic peripheral neuropathic pain in primary care – a retrospective cohort study using the United Kingdom General Practice Research Database
42. Utility functions for life years and health status: An additional remark
43. Priorities and prospect theory
44. The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer's Disease in Three European Countries – Study Design and Baseline Findings
45. Cost-Effectiveness of Duloxetine in Chronic Low Back Pain
46. Costs Associated With Treatment of Chronic Low Back Pain
47. Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom
48. Depression Treatment with Duloxetine and Reduction of Inability to Work
49. Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom
50. The Effect of Insulin Lispro on Glycemic Control in a Large Patient Cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.